相似文献
1
Tumor therapy of neoplastic diseases with tumor cells and neuraminidase. Further experimental studies on chessboard vaccination in canine mammary tumors.
Cancer Immunol Immunother. 1986;23(3):192-9. doi: 10.1007/BF00205649.
2
Tumor therapy of neoplastic diseases with tumor cells and neuraminidase: experimental studies on chessboard vaccination in transplantation tumors.
Int J Immunopharmacol. 1987;9(7):841-50. doi: 10.1016/0192-0561(87)90081-6.
3
Experimental cancer immunotherapy: modification of tumor cells to increase immunogenicity.
Ann N Y Acad Sci. 1976;276:45-60. doi: 10.1111/j.1749-6632.1976.tb41635.x.
4
Approaches to effective tumor immunotherapy with cells and the enzyme neuraminidase.
Adv Exp Med Biol. 1979;114:789-94. doi: 10.1007/978-1-4615-9101-6_129.
5
T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivo.
Cancer Immunol Immunother. 1987;25(3):231-41. doi: 10.1007/BF00199152.
6
Antigenicity of Ehrlich ascites through neuraminidase treatment of cells.
Indian J Exp Biol. 1979 Sep;17(9):953-5.
7
Possible immunological action of Vibrio cholerae neuraminidase (VCN) in tumor immunotherapy.
Dev Biol Stand. 1977;38:387-98.
8
Differential effect of neuraminidase on the immunogenicity of viral associated and private antigens of mammary carcinomas.
J Immunol. 1973 Dec;111(6):1820-5.
9
10
BCG versus VCN: the antigenicity and the adjuvant effect of both compounds.
Recent Results Cancer Res. 1980;75:53-60. doi: 10.1007/978-3-642-81491-4_9.
引用本文的文献
1
Targeted desialylation and cytolysis of tumour cells by fusing a sialidase to a bispecific T-cell engager.
Nat Biomed Eng. 2024 May;8(5):499-512. doi: 10.1038/s41551-024-01202-w. Epub 2024 May 1.
2
Enhancing CAR T function with the engineered secretion of C. perfringens neuraminidase.
Mol Ther. 2022 Mar 2;30(3):1201-1214. doi: 10.1016/j.ymthe.2021.11.014. Epub 2021 Nov 20.
3
Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment.
Cancer Metastasis Rev. 1990 Sep;9(2):125-36. doi: 10.1007/BF00046339.
本文引用的文献
1
The preparation and properties of two new chromogenic substrates of trypsin.
Arch Biochem Biophys. 1961 Nov;95:271-8. doi: 10.1016/0003-9861(61)90145-x.
2
The thiobarbituric acid assay of sialic acids.
J Biol Chem. 1959 Aug;234(8):1971-5.
3
The reproducibility and constancy of the platelet count.
Am J Clin Pathol. 1953 Jan;23(1):15-26. doi: 10.1093/ajcp/23.1.15.
4
BCG versus VCN: the antigenicity and the adjuvant effect of both compounds.
Recent Results Cancer Res. 1980;75:53-60. doi: 10.1007/978-3-642-81491-4_9.
5
The Thomsen-Friedenreich (TF) receptor: an old history with new mystery.
Immunol Commun. 1981;10(3):251-64. doi: 10.3109/08820138109093459.
6
Effect of Vibrio cholerae neuraminidase on the mitogen response of T-lymphocytes. II. Modulation of the lymphocyte response to macrophage released factors by neuraminidase.
Immunobiology. 1980 Dec;157(4-5):486-98. doi: 10.1016/S0171-2985(80)80017-9.
7
Effect of Vibrio cholerae neuraminidase on the mitogen response of T lymphocytes. I. Enhancement of macrophage T-lymphocyte cooperation in concanavalin-A-induced lymphocyte activation.
Immunobiology. 1980 Dec;157(4-5):474-85. doi: 10.1016/S0171-2985(80)80016-7.
8
T antigen, a tumor marker against which breast, lung and pancreas carcinoma patients mount immune responses.
Cancer Detect Prev. 1983;6(1-2):111-8.
9
Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy.
Cancer Immunol Immunother. 1983;15(3):172-7. doi: 10.1007/BF00199160.
10
Coexistence of immunogenic and suppressogenic epitopes in tumor cells and various types of macromolecules.
Cancer Immunol Immunother. 1983;16(1):1-10. doi: 10.1007/BF00199898.
Zotero 插件